Compare Marriott International Inc (MAR) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marriott International Inc vs Novo Nordisk A/S — how do they compare? Marriott International Inc trades at $361.34 (market cap $94.16B), while Novo Nordisk A/S trades at $38.05 (market cap $165.31B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Marriott International Inc for 164 Days and Novo Nordisk A/S for 116 Days on average.
| MAR | NVO | |
|---|---|---|
Market Cap | $94.16B | $165.31B |
Volume | 996,176 | 11,432,838 |
Sector | Consumer Cyclical | Health |
52-Week High | $402.54 | $63.98 |
52-Week Low | $259.04 | $35.29 |
Typical Hold Time | 164 Days | 116 Days |
Enterprise Value | $111.47B | $179.56B |
Dividend Yield | 0.81% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marriott International (MAR) trades at $356.5, down 1.32% on the day, with a bullish technical signal supported by moving averages. Revenue grew to $26.19B in 2025, with a net income margin of 9.62%. Recent earnings beat expectations in Q1 and Q2 2026, while Q3 results are pending. The company maintains strong cash flow from operations at $3.21B and announced a dividend of $0.73 per share payable in September 2026.
The outlook is positive with a consensus price target of $386.71, implying upside. Risks include high debt levels and competitive pressures. Analyst sentiment is mixed with 44% buy ratings, but institutional interest remains strong, supporting a cautiously optimistic view for long-term investors.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.96 surpassing the $0.82 estimate. The company maintains robust cash flow generation with $119.1B operating cash flow in 2025.
NVO presents compelling value with a 9.71 P/E ratio below industry averages and 59% analyst buy ratings. Upside potential exists to the $44.67 consensus target, though competition from Eli Lilly and FDA regulatory delays pose near-term risks. The obesity drug pipeline remains a key growth driver, supported by recent licensing deals totaling nearly $4B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
